Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

NCT01746784 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: N6022
DRUG: Normal saline

Sponsor

Nivalis Therapeutics, Inc.